OESO-SEMPIRE 17th World Conference | Esophagus 2026 | Versailles | June 14-17, 2026

All scientific sessions

DAY 1 – Monday, June 15 (Sessions 1 to 12)

Session 1: Oncology: Multimodal therapy

Monday, June 15, 9:00 – 10:30 am
Auditorium Lulli

Chairs: Markus Moehler (Germany) – Christelle De la Fouchardiere (France) – Manfred Lutz (Germany) 

  1. Early-onset gastroesophageal cancer – a distinct entity? – Irit Ben-Aharon (Israel)
  2. Pro: First choice Chemo (instead of CROSS) in adenocarcinoma of esophagus. – Eduardo Terán (Spain)
  3. Contra: First choice CROSS (instead Chemo) in adenocarcinoma of esophagus. – Mike Gibson (USA)
  4. Recurrences after neoadj therapy: local endoscopic resections or irradiation? – Manfred Lutz (Germany)
  5. Management of Metastatic Disease. – Aziz Zaanan (France)
  6. De-escalation strategies in oesogastric adenocarcinomas: is the time right? – Christelle De la Fouchardiere (France)
  7. MSI: how do we treat, w+w or operate? – Thierry André (France)
  8. ASCO 2026: New important SOC-changing phase III trials? – Lucjan Wyrwicz (Poland)
  9. Multidisciplinary Tumor Board-Harmonizing other Local and Systemic Control in Gastric or Gastroesophageal Cancer. – Hanoch Kashtan (Israel)
  10. Sport program and Resilience: what helps in perioperative setting? – Katja Petrowski (Germany)
     

Session Format:
Presentations: Eleven topics will be addressed with prepared presentations.
Each speaker will be given 8 minutes to discuss the assigned topic.

Session 2: Functional Disorders – From Brain to Diaphragm and Back

Monday, June 15, 9:00 – 10:30 am
Auditorium Richelieu

Chairs: Walter W. Chan (USA) – C. Prakash Gyawali (USA)

  1. Belch or no belch: what is the approach to belching disorders? – Santosh Sanagapalli (Australia)
  2. When to suspect and confirm the diagnosis of rumination? – Akinari Sawada (Japan)
  3. How do symptom-specific anxiety and hypervigilance intersect with esophageal conditions? – Livia Guadagnoli (USA)
  4. What is the role of brain-gut behavioral therapy in treating esophageal symptoms? – Megan Riehl (USA)
  5. How to leverage pharmacologic neuromodulation for esophageal symptoms. – José María Remes Troche​ (Mexico)
  6. Are there roles for complementary therapies for treating esophageal symptoms? – Chien-Lin (Harry) Chen (Taiwan)

Panel Chat/Q&A

Session 3: Distinguished Abstracts Plenary – Basic and Translational Science

Monday June 15, 09:00 – 10:30 am
Auditorium Condé

Session Format: 
Presentations: Distinguished basic and translational science abstracts will be presented.
Each speaker will be assigned 15 minutes (including Q&A)
 

Chairs: Mayssan Muftah (USA) – Nikki Johnston (USA)

  1. ​Prostaglandin E₂ Reverses Myofibroblast Differentiation in Eosinophilic Esophagitis. – Amanda Muir (USA)
  2. VDTR-Net: An Integrated Dose-Toxicity Deep Learning Framework for Pre-Radiotherapy Planning Risk Assessment of Severe Radiation Pneumonitis in Esophageal Cancer. – Yanhua Duan (China)
  3. Spatial analysis of CD8+ T cell neighbors using multiplexed immunofluorescence (MxIF) in esophageal squamous cell carcinoma (ESCC). – Michael Gibson (USA)
  4. Amprenavir Protects Human Airway Cells from Pepsin-Induced Inflammation and Early Epithelial-Mesenchymal Transition. – Karolina Lungova (USA)
  5. IL-13 induced β-catenin drives esophageal epithelial disruption. – Amanda Muir (USA)
  6. Machine Learning to Predict Distant Metastasis Risk and Prognostic Analysis in T1 2 Esophageal Cancer: A Study Based on the SEER Database. – Benben Zhu (China)
  7. Manometry-Only Distensibility Assessment: Inverted-Impedance 4D Manometry for Detecting Distension-Mediated Obstruction When the Functional Lumen Imaging Probe (FLIP) Is Unavailable. – So Young Byun (Korea)

 

Session 4: Distinguished Abstracts Plenary – Clinical Research

Monday, June 15, 11:00 am – 12:30 pm
Auditorium Lulli

Session Format:
Presentations: Nine distinguished basic and translational science abstracts will be presentations.
Each speaker will be assigned 10 minutes (including Q&A). 
 

Chairs: Ealaf Shemmeri (USA) – Pierfrancesco Visaggi (Italy)

  1. Prolonged One-Lung Ventilation Increases the Risk of Postoperative Pneumonia in Minimally Invasive and Robotic Esophagectomy. – Vladimir Lozanovski (Germany)
  2. Higher Rates Of PPI Nonresponse With Proximal Stricture Compared To Distal Or No Stricture In Adults With Eosinophilic Esophagitis. – David Hartnett (USA)
  3. Proposal of a Novel Endoscopic Classification to Assess Laparoscopic Fundoplication Validated with Clinical and Functional Outcomes. – Stefano Siboni (Italy)
  4. Inverted Impedance–Based 4D Manometry Improves Achalasia Diagnosis by Assessing Esophagogastric Junction Distensibility When the Functional Lumen Imaging Probe (FLIP) Is Unavailable. – So Young Byun (Korea)
  5. Clinical Outcomes After Curative and Noncurative Endoscopic Submucosal Dissection for Superficial Esophageal Cancer. – Po-Kuei Hsu (Taiwan)
  6. A Retrospective Cohort Study Evaluating Textbook Outcomes and Long-Term Prognosis Following Esophagectomy. – Benjamin Tordjman (Canada)
  7. High Dimensional Clustering Identifies Distinct Clinical Physiologic Phenotypes of Eosinophilic Esophagitis. – Mayssan Muftah (USA)
  8. Efficacy of anti-reflux surgery on Laryngo-Pharyngeal Symptoms of Gastro-Esophageal Reflux Disease. – Marco Sozzi (Italy)
  9. Diagnostic Performance of a Tegoprazan Based Therapeutic Trial in Patients with Suspected GERD: Interim Analysis of the Prospective Multicenter Phase IV TEGO-TEST study. – Luis Raúl Valdovinos-Garcia (Mexico)

​

 

Session 5: Functional Disorders – Talking Rome in Versailles

Monday, June 15, 11:00 am – 12:30 pm
Auditorium Richelieu

Chairs: Daniel Sifrim (UK) – C. Prakash Gyawali (USA)

  1. How should non-cardiac chest pain be diagnosed? – Ronnie Fass (USA)
  2. How is functional heartburn different from reflux-induced heartburn? – Ellen M. Stein (USA)
  3. Should reflux hypersensitivity be managed as a DGBI, GERD, or both? – Edoardo Savarino (Italy)
  4. Is globus a LPRD symptom or a primary DGBI? – José María Remes Troche (Mexico)
  5. What test(s) should be performed to diagnose functional dysphagia? – Sabine Roman (France)
  6. How does functional dyspepsia overlap with esophageal symptoms or disorders? – Braden Kuo (USA)

Panel Chat/Q&A

Session 6: Therapeutic Endoscopy: New Frontiers

Monday June 15, 11:00 am – 12:30 pm
Auditorium Condé

Chairs: Mouen Khashab (USA) – Philip Chiu (Hong Kong) – Joo Ha Hwang (USA) – Byung-Wook Kim (Korea)
Discussants: Helmut Messmann (Germany) – Sung Kwan Shin (Korea)
 

   I. POEM and Third-Space Procedures

  1. Does the side of mucosal entry affect POEM procedure outcomes? – Toshitaka Hoppo (USA)
  2. What is the true incidence of reflux after POEM & how can that be reduced? – Mouen Khashab (USA)
  3. Does it matter whether full-thickness or circular muscle-only myotomy is performed for POEM? – Philip Chiu (Hong Kong)
  4. Do we know the long-term durability of POEM? – Tomoaki Matsumura (Japan)
  5. Can we predict which patients will fail POEM? – Ahmad Najdat Bazarbashi (Saudi Arabia)
  6. Should we aim for same day discharge after POEM? – Silvana Perretta (France)​​


    II. Endoscopic Submucosal Dissection & Tumor Resection
     
  7. How large is too large for ESD in 2026? – Cheol Woong Choi (Korea)
  8. How deep is too deep for ESD in 2026? – Ahmad Najdat Bazarbashi (Saudi Arabia)
  9. Is endoscopic ultrasound helpful or required for optimal ESD? – Helmut Messmann (Germany)
  10. Will artificial intelligence change the way we perform ESD? – Moon Kyung Joo (Korea)
  11. What technological advances are needed for ESD to make the next leap forward? – Shai Friedland (USA)
  12. What are the next steps for 3rd space endoscopy in the esophagus? – Anthony Kalloo (USA)

Session 7: Laryngopharyngeal Reflux Disease (LPRD): Cutting Through the Noise

Monday, June 15, 2:00 – 3:30 pm
Auditorium Lulli

Chairs: Frank Zerbib (France) – Nikki Johnston (USA)

  1. What does the San Diego Consensus change in clinic? – Thomas L. Carroll (USA)
  2. What is the value in establishing a new ICD-10 CM code for LPRD? Alexandra Vandenberg (USA)
  3. Is GMA biomarker subtyping the key to understanding and treating GERD/LPR? – Mark Noar (USA)
  4. Alginate, H2RA, PPI, neuromodulation, or lifestyle first – what’s your first script? – Jacqueline Allen (New Zealand)
  5. What is the role of sedated POEM procedures for UES issues? – Pavan Mallur (USA) 
  6. What is your oropharyngeal dysphagia management protocol for LPR? – Derrick Randall (Canada) 
  7. What are the pathogenic elements of refluxate in LPRD: acid, pepsin, bile, and beyond? – Tina Samuels (USA) 
  8. What is the status of pepsin inhibitors for LPR? – Nikki Johnston (USA)
  9. What is the current understanding of the role of reflux in promoting laryngopharngeal cancer? – Jérôme R. Lechien (Belgium) 
  10. Which surgical or endoscopic options work for extra-esophageal disease? – Stefano Siboni (Italy)

Structured Debate:

Motion: “This house supports the San Diego Consensus Statement as the governing guideline for LPRD.”

  • FOR: Walter W. Chan (USA) – (defending the Consensus statements & pathways).
  • AGAINST: Mark Noar (USA) – (challenging external validity, symptom-first pathways, and laryngology-specific nuances).

Case-Based Panel + Audience Interaction:

All panelists on stage for questions and discussion: Jonathan Bock (USA) – Jacqui Allen (New Zealand) – Mark Noar (USA) – Edoardo Savarino (Italy) – Serhat Bor (Turkey) – Stefano Siboni (Italy) – Jérôme R. Lechien (Belgium) – Thomas L. Carroll (USA)

  1. Chronic cough with normal acid exposure but high non-acid events: “Does therapy change?”
    Panel lead: Jonathan Bock (USA) 
  2. Mucosal protection: formulations and their place in the management of GERD and LPR.
    Panel lead: Serhat Bor (Turkey)
  3. Refractory LPS after maximal PPI & alginate: “Is it time for surgery or is it not reflux?”
    Panel lead: Stefano Siboni (Italy)

 

Session 8: Robotic Surgery

Monday, June 15, 2:00 – 03:30 pm
Auditorium Richelieu

Chairs: Inderpal (Netu) Singh Sarkaria (USA) – Matthew Read (Australia) – Andrés Francisco Navarrete Molina (Chile)   

  1. Why and when to resect thoracic duct during RAMIE and in which anatomical plane? – Hiroyuki Daiko (Japan)
  2. da Vinci Single Port subcostal Esophagectomy – How to and first result s? – Jasmina Kuvendjiska (Germany)
  3. Cardia Cancer – how to treat different compared to esophageal AC? – Andrés Francisco Navarrete Molina (Chile)    
  4. Vision of Robot Assisted Cervical Esophagectomy (RACE). – Peter Grimminger (Germany)
  5. Results of the randomized prospective multi-center ROBOT-2 Trial of MIE vs RAMIE. – Felix Berlth (Germany) 
  6. Different robotic systems (also for esophageal surgery) what does make sense? – Simone Giacopuzzi (Italy)    

Panel Chat/Q&A

Session 9: KCHUGR-OESO Joint Session on Global Perspectives in Advanced Endoscopic Techniques

Monday June 15, 2:00 – 3:30 pm
Auditorium Condé

Chairs: Byung-Wook Kim (Korea) – Hwoon-Yong Jung (Korea) – Stefan Mönig (Switzerland)
Discussants: Sung Kwan Shin (Korea) – Eun Ji Shin (USA) – Helmut Messmann (Germany) 

  1. ESD in superficial esophageal cancer – reflecting Korea’s high volume and advanced endoscopic techniques. – Da Hyun Jung (Korea)
  2. EMR vs ESD for superficial esophageal cancer in the West. – Seung-Hun Chon (Germany)
  3. Real-world evidence of POEM for achalasia. – Hyo-Joon Yang (Korea)
  4. Endoscopic management of Zenker’s Diverticula. – Mouen Khashab (USA)
  5. AI-assisted endoscopic diagnosis of esophageal dysplasia or cancer. – Chang Seok Bang (Korea)
  6. Evaluation and management of esophageal subepithelial masses. – Walter Park (USA)

Keynote Lecture: Evaluation and management of recurrent dysphagia in patients with achalasia previously treated with POEM. – Joo Ha Hwang (USA)

Session 10: Pilot centers

Monday, June 15, 4:00 – 05:30 pm
Auditorium Lulli

  • Introduction and new perspectives.
    Nikki Johnston (USA) – Robert Giuli (France) – Dhanpat Jain (USA)         
                         
  • Technological updating of the OESO-SEMPIRE Platform.                                     
    Rahul Bharadwaj (Malaysia)
     
  • Proposals from Pilot Centers.
    Jérôme R. Lechien (Belgium) – Frank G. Ondrey (USA) – Peter Pokieser (Austria)
     
  • Chat discussion.  
    Philip Chiu (Hong Kong) – Suzanne Gisbertz (the Netherlands) – Ines Gockel (Switzerland) – Matthew Read (Australia) – Russell E. White (Kenya) – Frank Zerbib (France) – Bruno Zilberstein (Brazil) 

                                                           

Session 11: Robotic Surgery

Monday, June 15, 4:00 – 05:30 pm
Auditorium Richelieu

Chairs: Flavio Takeda (Brasil) – Yusef Kudsi (USA) – Peter Grimminger (Germany)

  1. ICG during RAMIE. – Jennifer Klasen (Switzerland)
  2. RAMIE in South America vs. North America. 
    – Rubens Sallum (Brazil) – Inderpal (Netu) Singh Sarkaria (USA)
  3. RAMIE in difficult Cases – Proximal esophagus. – Felipe Victer (Brazil)
  4. New Techniques treating early cancer with robotic surgery vs. endoscopy. – Silvana Peretta (France)
  5. Benign Foregut – Robotic Update. – Tanuja Damani (USA)                    
  6. Implementation of AI / Digital Assist in robotic surgery / Innovation. – Tilman Schlick (Germany)

Panel Chat/Q&A

Session 12: Eosinophilic Esophagitis: State of the Art

Monday June 15, 4:00 – 5:30 pm
Auditorium Condé

Chairs: Nirmala Gonsalves (USA) – Pierfrancesco Visaggi (Italy)
Discussants: Jennifer Horsley-Silva (USA) – Emily McGowan (USA)

    I. Diagnosis, Clinical Presentation & Pathophysiology

  1. What is the true prevalence of EoE and is it increasing? – Mayssan Muftah (USA)
  2. What do we know about the microbiome in EoE or assessing endoscopic severity? – Alex Strauss (USA)
  3. Is an allergist required for care of the EoE patient in 2026? – Emily McGowan (USA)
  4. What are the advantages of "EoE Diagnostic Panel (EDP)” over peak eosinophil count for EOE diagnosis? – Kevin Waters (USA)
  5. What is the role for non-endoscopic techniques for diagnosis & surveillance? – John O. Clarke (USA) 
  6. Challenges in evaluating biopsies in suspected EOE cases? – Kevin Waters (USA)

    Panel Chat/Q&A


    II. Management
  7. Is there still a role for proton pump inhibitors in the management of EoE? – Ellen Stein (USA)
  8. Topical steroids: who, what & how long? – Jennifer Horsley-Silva (USA)
  9. How to approach biologic therapies for EoE in 2026? – Joshua Sloan (USA)
  10. How I approach endoscopic dilation for EoE – William Ravich (USA)
  11. What to do with the EoE patient who becomes pregnant? – Claire Beveridge (USA)
  12. Is EoE therapy forever? – Calies Menard-Katcher (USA)

   Panel Chat/Q&A

 

DAY 2 – Tuesday, June 16 (Sessions 13 to 24)

Session 13: GI Clinical Pharmacology & Therapeutics

Tuesday June 16, 9:00 – 10:30 am
Auditorium Lulli

Chairs: Carmelo Scarpignato (Malta) – C. Prakash Gyawali (USA)
 

I – Acid Suppression: Present and Future

  1. Acid Suppression: Limitations of the Current Antisecretory Drugs. Why do PPIs fail in some patients, and what are the true boundaries of acid suppression? – Justin Wu (Hong Kong)
  2. Potassium-competitive Acid Blockers (P-CABs): A Step Forward in Acid Suppression. Do they really represent a paradigm shift or just an incremental advance? – Carmelo Scarpignato (Malta)
  3. P-CABs for GERD: When and How. Patient profiles, timing, and switching strategies. – Ronnie Fass (USA)
  4. Alginate-containing Formulations: Before, With, or After PPIs? Optimizing the synergy between mechanical and pharmacologic acid control. – Serhat Bor (Turkey)

    II – Mucosal Protection and Beyond 
  5. Mucosal Protective Compounds for GERD: How Much Are They Effective? Evidence and clinical relevance of sucralfate, hyaluronic acid–chondroitin sulfate, and similar agents. – Daniel Sifrim (UK)
  6. The Status of Pepsin Inhibitors for PPI-Refractory GERD and LPR. A promising approach or another dead end? – Nikki Johnston (USA)

    III – Motility & Neuromodulation
  7. GI Prokinetics: Which Role in GERD? From metoclopramide to acotiamide—any real progress? José María Remes Troche (Mexico)
  8. When Are Neuromodulators Indicated in GERD? Functional heartburn, reflux hypersensitivity, and esophageal perception. C. Prakash Gyawali (USA)

    IV – Eosinophilic Esophagitis (EoE)
  9. PPIs or Steroids for EoE: Alone or in Combination? Balancing efficacy, safety, and long-term management. Nirmala Gonsalves (USA)
  10. EoE: When to Start Biologic Therapy and How? Current position of anti–IL-13/IL-4 agents and future perspectives. Nicola De Bortoli (Italy)

    V – Motor Disorders & New Frontiers
  11. Smooth Muscle Relaxants for Achalasia: Still a Bridge Treatment? Are pharmacologic options still relevant in the POEM era? Mark Fox (Switzerland)
  12. Long-term Safety and Pharmacogenetics of Acid Suppression. Are we ready for tailored therapy and precision acid suppression? Walter W. Chan (USA)
  13. Reflux Inhibitors: A Promise Unfulfilled or a Niche Therapy? Targeting TLESRs: Translational Failures and Clinical Residues. – Ellen M. Stein (USA)

Session 14: Esophageal Cancer – Best Surgical Treatment for Esophageal Adenocarcinoma

Tuesday June 16, 9:00 – 10:30 am
Auditorium Richelieu

Chairs: Arnulf Hölscher (Germany) – Giovanni De Manzoni (Italy) – Stefan Mönig (Switzerland) 

  1. Which classification system we need 2026? – Giovanni De Manzoni (Italy) 
  2. Double Tract reconstruction after limited resection. – Johannes Zacherl (Austria)
  3. How long we can wait after neoadjuvant treatment for surgery and how long we should wait? – Mickael Chevallay (Switzerland)
  4. Which access is the best open, HYBRID or minimal invasive? – Frank Benedix (Germany)
  5. What is the safest anastomotic technique after esophagectomy? – Paul Schneider (Switzerland)
  6. How we can prevent and treat Enterothorax after Esophagectomy? – Christian Gutschow (Switzerland)

Panel Chat/Q&A

 

 

Session 15: Techniques and Tips in Esophageal Practice: GERD, Antireflux Surgery, and Esophageal Cancer

Tuesday June 16, 9:00 – 10:30 am
Auditorium Condé

Chairs: Roger Tatum (USA) – Benjamin Rogers (USA) 

  1. How to approach Tissue Cypher in the low vs. high risk patients with Barrett’s esophagus. – Allon Kahn (USA)
  2. How to approach chronic belching, what’s my personal approach. – Johannes Lenglinger (Switzerland) 
  3. How I work up and manage the manometric finding of absent peristalsis. – Ping-Huei Tseng (Taiwan)
  4. How I approach refractory reflux, before pre-operative work up. – Rishi Naik (USA)
  5. Patient selection for magnetic sphincter augmentation vs. fundoplication. – Kourtney L. Kemp (USA)
  6. When and how to remove the magnetic sphincter augmentation device. – Nainika Menon (UK)
  7. Workup and surgical procedure selection in GERD patients with morbid obesity. – Judy Chen (USA)
  8. Patient selection for and technique of the reflux stop procedure. – Yves Borbely (Switzerland)
  9. Management of patients with post-antireflux surgery gastroparesis. – Jacob Moremen (USA)

 

 

Session 16: Artificial Intelligence and Digital Technology in Esophagology

Tuesday, June 16, 11:00 am – 12:30 pm
Auditorium Lulli

Chairs: Lee L. Swanström (France) – Gretchen Purcell Jackson (USA)

  1. Current status of AI in Medicine/ barriers and opportunities. – Filippo Filicori (USA)       
  2. AI and Digestive radiology – better? Easier? – Peter Pokieser (Austria)             
  3. AI and Barretts – where are we? – Jason Samarasena (USA) 
  4. AI for esophageal function testing. – Benjamin Rogers (USA) 
  5. AI for reflux monitoring interpretation. – Benjamin Rogers (USA)
  6. Can AI make me a better esophageal surgeon? – Jonathan Delong (USA)
  7. AI and the robot – synergy? – Gretchen Purcell Jackson (USA) 
  8. AI and coordinated care of the esophagus. – Eric Shah (USA)  
  9. Can AI improve the pathologic diagnosis of BE and how?” – Maha M. Guindi (USA) 
  10. Can a digital morphometry in AI improve the histological diagnosis of EoE? – Rupert Langer (Austria)
  11. AI and EGD quality – Lee L. Swanström (France)

Panel discussion: Favorite AI tool for my practice.

Moderators: Lee L. Swanström (France) – Gretchen Purcell Jackson (USA)
Discussants: Jonathan Delong (USA) – Benjamin Rogers (USA) – Jason Samarasena (USA) – Eric Shah (USA) – Rupert Langer (Austria) – Anastasia Bartashova (Austria) – Filippo Filicori (USA)     

Session 17: Esophageal Cancer – Special Aspects for Treatment of Squamous Cell Esophageal Carcinoma

Tuesday, June 16, 11:00 am – 12:30 pm
Auditorium Richelieu

Chairs: Vincent Wentao Fang (China) – Peter Grimminger (Germany) – Guido Schumacher (Italy)​

  1. Is there a place for surgery in proximal cancer? – Ian Wong (Hong Kong) 
  2. When we need McKeown, when Ivor-Lewis approach is sufficient? – Rubens Sallum (Brazil)
  3. What is necessary extent of lymphadenectomy in thoracic esophageal cancer? – Ines Gockel (Switzerland)
  4. Technical aspects of cervical anastomosis after McKewon esophagectomy? – Jari Räsänen (Finland)
  5. What are the arguments for surgery in squamous cell carcinoma? – Guillaume Piessen (France)
  6. What are the pitfalls for salvage esophagectomy? – Felix Berlth (Germany) 

Panel Chat/Q&A

Session 18: KSNM-OESO Joint Session: Esophagology – East vs West

Tuesday June 16, 11:00 am – 12:30 pm
Auditorium Condé

Chairs:
OESO representatives: Kerry Dunbar (USA) – Amanda Muir (USA)
KSNM representatives: Moo In Park (Korea) – Sang Kil Lee (Korea)
Discussants:
OESO representative: Albis Hani (Colombia)
KSNM representative: Jung-Hwan Oh (Korea)
 

   GERD

  1. Approach to GERD in the Western population: what’s beyond Lyon? – C. Prakash Gyawali (USA)
  2. Clinical Limitations of the Lyon Consensus 2.0 in Asian Populations. – Yu Kyung Cho (Korea)


    Motility
  3. When testing modalities disagree: Rethinking diagnostic hierarchies in esophageal physiology. – Walter W. Chan (USA)
  4. Esophageal motility diagnostics in Asia: Epidemiology, testing trends, and unmet needs. – Ju Yup Lee (Korea)


    Eosinophilic Esophagitis
  5. Phenotypes of eosinophilic esophagitis: Impact on presentation, diagnosis, and management. – Amanda Muir (USA)
  6. Eosinophilic esophagitis in Asia: Distinct clinical and endoscopic profiles compared with the West. – Kee Wook Jung (Korea)
    ​

Keynote Lecture: (by KSNM speaker): Do Hoon Kim (Korea)
Comparative Effectiveness of P-CAB vs PPI: Real-World Evidence

Session 19: Surgical Endoscopy: Pushing the envelope of what can be done with the endoscope

Tuesday, June 16, 2:00 – 3:30 pm
Auditorium Lulli

Chairs: Eun Ji Shin (USA) – Lee L. Swanstrom (France) – Toshitaka Hoppo (USA)

Endoscopic Reflux Therapy

  1. Is anti-reflux mucosectomy ready for prime-time? – Ping-Huei Tseng (Taiwan)
  2. Who is the ideal patient for transoral incisionless fundoplication (TIF)? – Medhat Fanous (USA)
  3. Why do c-TIF instead of a standard fundoplication? – Reginald Bell (USA)
  4. What is the long-term success & durability of TIF? – Kenneth Chang (USA)
  5. How large a hernia is too large to address with c-TIF? – Marcia (Mimi) Canto (USA)
  6. Can AI help us better predict which endoscopic therapy is most likely to be successful? – Lee L. Swanström (France)
     

Complications of Endoluminal Intervention

  1. How to approach mucosal erosion from the magnetic device? – Emanuele Asti (Italy)
  2. What are the key complications to be aware of from TIF or cTIF? – Reginald Bell (USA)
  3. How to approach a blown-out myotomy? – Daryl Ramai (USA)
  4. What is the optimal way to address significant reflux after POEM? – Valter N. Felix (Brazil)

​
Keynote Talk: What will the frontiers of surgical endoscopy be in the next 20 years? – Philip Chiu (Hong Kong)

 

Session 20: Eosinophilic Esophagitis – Hot Topics & Unanswered Questions

Tuesday June 16, 2:00 – 3:30 pm
Auditorium Richelieu

Chairs: John O. Clarke (USA) – Walter W. Chan (USA)

  1. Do we really know what causes EoE? – Amanda Muir (USA)
  2. What is the role for allergy testing for EoE patients? – Emily McGowan (USA)
  3. How should one ideally pursue an EoE-elimination diet? – Claire Beveridge (USA)
  4. How to approach medical therapy for EoE: my algorithm? – Christoph Schlag (Switzerland)
  5. What is the role for artificial intelligence in EoE? – Pierfrancesco Visaggi (Italy)
  6. How will we treat EoE in 10 years? – Nirmala Gonsalves (USA)

Panel Chat/Q& A

Session 21: Dynamic Imaging 1 – Dynamic Esophagology Morphology

Tuesday June 16, 2:00 – 3:30 pm
Auditorium Condé

Chairs: Peter Pokieser (Austria) – Johannes Zacherl (Austria)

  1. What is the additional value of dynamic radiology for the esophagus with 25 or 30 frames per second? – William Ravich (USA)
  2. Why dynamic radiology is the best test to measure single and multiple stenoses of the esophagus? – Peter Pokieser (Austria)
  3. Is there any use of dynamic fluoroscopy in patients with esophageal carcinoma? – Inderpal (Netu) Singh Sarkaria (USA)
  4. Surgery of benign diseases of the PE-segment: what are the demands for dynamic radiology? – Johannes Zacherl (Austria)
  5. Bariatric surgery: is there a role for dynamic radiology for late postoperative complications? – Peter Pokieser (Austria)
  6. Esophagology and Gastroenterology: are there indications for dynamic radiology? – Ludwig Kramer (Austria)

Panel Chat/Q&A

Session 22: Oncology – Palliative treatment options

Tuesday, June 16, 4:00 – 5:30 pm
Auditorium Lulli

Chairs: Manfred Lutz (German) – Anneli Elme (Estonia) – Mike Gibson (USA)

  1. ESMO standards of care: equal to other countries in the world? – Jonas Feilchenfeldt (Switzerland) 
  2. Eastern Perspectives on Esophageal Cancer – Exploring Regional Differences in Clinical Characteristics and Treatment Strategies, with a Focus on ESD. – Hwoon-Yong Jung (Korea)
  3. Molecular response prediction in esophageal squamous cell carcinomas: results of the EORTC/SAKK POWER project. – Alexander Siebenhuener (Switzerland)
  4. IO tailored personalized medicine included side effects, drug holidays and maintenance. – Markus Moehler (Germany)
  5. Oligometastatic disease: recommendations or studies ahead? – Şuayib Yalçın (Turkey)
  6. Surveillance after “cure”? – Anneli Elme (Estonia) 
  7. Overview of the ECOG-ACRIN Microbiome Working Group Clinical Trials – Mike Gibson (USA)
  8. Biomarker in advanced esophageal cancers: what do we need to know. – Rupert Langer (Austria) 
  9. Oral Abstract Presentation: Macrophage Infiltration and FoxP3 Density Predict Treatment Response and Survival in Esophageal Cancer Patients. – Styliani Mantziari (Switzerland)
  10. Oral Abstract Presentation: Prognostic Impact of Treatment Modalities and Examined Lymph Nodes Count on Survival in T3–4 Esophageal Cancer: A Retrospective Cohort and Predictive Modeling Study from the SEER Database. – BenBen Zhu (China)

 

Session Format:
Presentations: Ten topics will be addressed with prepared presentations.
Each speaker will be given 9 minutes to discuss the assigned topic. 
 

 

 

Session 23: GERD – When Standard Therapy Fails

Tuesday, June 16, 4:00 – 5:30 pm
Auditorium Richelieu

Chairs: Walter W. Chan (USA) – C. Prakash Gyawali (USA)

  1. When do PPI fail and when should PCAB be considered in treating reflux symptoms? – Enrique Coss-Adame (Mexico)
  2. How should reflux symptoms refractory to PPI be evaluated? – Justin Wu (Hong Kong, China)
  3. What other primary or adjunctive non-surgical options are useful for reflux symptoms? – Mark Fox (Switzerland)
  4. What are the causes of failed fundoplication? – Tanuja Damani (USA)
  5. How should symptomatic post-fundoplication patients be assessed? – Salvatore Tolone (Italy)
  6. When should endoscopic anti-reflux interventions be considered? – Kenneth Chang (USA)

Panel Chat/Q&A

Session 24: Dynamic Imaging 2 – Functional Disorders

Tuesday June 16, 4:00 – 5:30 pm
Auditorium Condé

Chairs: Nathalie Rommel (Belgium) – Jacqueline Allen (New Zealand)

  1. Does videomanometry cover Deglutology and Esophagology in one test? – Nathalie Rommel (Belgium)
  2. What are the strengths of dynamic radiology in evaluation of esophageal motility disorders? – Peter Pokieser (Austria)
  3. Neurogastrology in multilevel dysphagia of Morbus Parkinson: can videofluoroscopy contribute for the clinical work up? – Peter Pokieser (Austria)
  4. Dynamic Radiology in Reflux disease: the surgical demands. – Johannes Zacherl (Austria)
  5. Late postoperative complications after reflux surgery: what is the current role of dynamic radiology? – Peter Pokieser (Austria)
  6. What is the complementary role of VFFS to FEES in neurologic patients? – Jacqueline Allen (New Zealand)

Panel Chat/Q&A

 

DAY 3 – Wednesday, June 17 (Sessions 25 to 33)

Session 25: Esophageal Motility Disorders: Controversies and Challenges (this or that)

Wednesday, June 17, 9:00 – 10:30 am
Auditorium Lulli

Chairs: Joshua Sloan (USA) – Daniela Jodorkovsky (USA) – Ellen M. Stein (USA)
Discussants (part. 1): Joshua Sloan (USA) – Jorge Luis​ Espinoza-Rios (Peru)

  1. When to FLIP – up-front, at the end, any time, or never? – Anh Nguyen (USA)
  2. Advantages of barium esophagram versus FLIP for EGJ outflow obstruction. – Kristle Lynch (USA)
  3. Achalasia subtyping: FLIP + Barium versus HREM alone. – Alberto Barchi (Italy)
  4. Achalasia treated, recurrent– how to evaluate? – Daniela Jodorkovsky (USA)
  5. Achalasia treated, recurrent - recut or dilate? – Claudia Barber-Caselles (Spain)
  6. Treatment of spastic disorders in the esophagus (non-achalasia): pharmacologic versus endoscopic interventions – Joan Chen (USA)

    Discussants (part. 2): Daniela Jodorkovsky (USA) – Joan Chen (USA)
     
  7. Only time for one provocative maneuver today – how do you choose – MRS, Rapid drink or SLR?  – Daphne Ang (Singapore)
  8. Treatment or observation for Ineffective Esophageal Motility, which is better? – Jorge Luis​ Espinoza-Rios (Peru)
  9. Pre-operative testing for GERD: esophageal manometry AND imaging or is less more. – Albis Hani (Colombia)
  10. Absent contractility and proven GERD: lifestyle modification and medical management or wrap? – Reena Chokshi (USA)
  11. Should we care more or less about bolus clearance during HREM? – Karthik Ravi (USA)
  12. An abnormal looking manometry that is NORMAL by Chicago 4.0 Explore or ignore. – Luis Raúl Valdovinos García (Mexico)

Session 26: State of the Art Surgery

Wednesday, June 17, 9:00 – 10:30 am
Auditorium Richelieu

Chairs: Arnulf H. Hölscher (Germany) – Paulo Morgagni (Italy) – Moustafa Elshafei (Germany)

  1. Current Art of Antireflux Surgery. – Burkhard H.A. von Rahden (Germany)
  2. Current Art of Surgery for Achalasia. – Aleksandar P. Simić (Serbia)
  3. Current Art of Surgery for Esophageal Diverticula. – Rubens Sallum (Brazil)
  4. Current Art of Surgery for Esophageal Squamous Cell Carcinoma. – Simone Giacopuzzi (Italy)
  5. Current Art of Surgery for Esophageal and Junctional Adenocarcinoma. – Katharina Beyer (Germany)

Panel Chat/Q&A

Session 27: Barrett’s Esophagus: Physiology & Diagnosis

Wednesday, June 17, 9:00 – 10:30 am
Auditorium Condé

Chairs: Margaret Zhou (USA) – Emanuele Asti (Italy) – Kee Wook Jung (Korea)

  1. Do we know the precursor of Barrett’s esophagus? – Ines Gockel (Germany)
  2. Is intestinal metaplasia of the EGJ truly Barrett’s esophagus – and does it matter? – Maha M. Guindi (USA)
  3. What is the role of the microbiome in Barrett’s esophagus & can it be a target for screening or therapy? – Margaret Zhou (USA)
  4. Who should be screened for Barrett’s esophagus? – Kenneth Vega (USA)
  5. What is the current role for non-invasive Barrett’s screening modalities? – Prasad Iyer (USA)
  6. How should endoscopy be performed for patients with suspected or known Barrett’s esophagus? – Marcia (Mimi) Canto (USA)
  7. How should we assess risk of progression after diagnosis? – Kerry Dunbar (USA)
  8. What is the role of endoscopic ultrasound in Barrett’s esophagus & should it be mandatory? – Eun Ji Shin (USA)
  9. How to choose between radiofrequency ablation & cryotherapy for ablation? – Shai Friedland (USA)
  10. Should nodular Barrett’s be removed with EMR or ESD? – Daryl Ramai (USA)
  11. Should all patients with Barrett’s esophagus be offered anti-reflux surgery? – Emanuele Asti (Italy)
  12. Are there patients for whom we can recommend against future surveillance? – Massimiliano Di Pietro (UK)

Panel Chat/Q&A

 

Session 28: Obesity and the Esophagus

Wednesday, June 17, 11:00 am – 12:30 pm
Auditorium Lulli

Chairs: Minoa K. Jung (Switzerland) – Silvana Perretta (France) – Anthony Kalloo (USA) 

  1. How does obesity impact esophageal physiology? – Eric Sheu (USA)
  2. Should esophageal physiologic testing be routinely performed prior to bariatric intervention? – Brent Hiramoto (USA) 
  3. What are the consequences of intragastric balloons on esophageal and gastrointestinal symptoms? – Allison Schulman (USA)
  4. Do endoscopic gastric remodeling procedures cause esophageal symptoms? – Allison Schulman (USA)
  5. How should dysphagia following bariatric surgery be evaluated? – Claudia Barber-Caselles (Spain)
  6. Can bariatric surgery cause achalasia and achalasia-like disorders? – Karthik Ravi (USA)


    Panel Chat/Q&A
  7. What are the mechanisms underlying excessive reflux following bariatric surgery? – Minoa K. Jung (Switzerland)
  8. How should reflux following bariatric surgery be managed? – Silvana Perretta (France)
  9. What is the approach to a hiatal hernia following bariatric surgery? – Salvatore Tolone (Italy)
  10. How do weight regain and associated interventions affect esophageal symptoms? – Ahmad Bazarbashi (Saudi Arabia)
  11. What are the esophageal and gastrointestinal side effects of GLP-1 receptor agonist use? – Nayna Lodhia (USA)
  12. What is the impact of obesity and weight loss interventions on the risk of Barrett’s esophagus and esophageal cancer? – Nitin Ahuja (USA)
Panel Chat/Q&A

 

Session 29: Barrett’s Esophagus: Management

Wednesday, June 17, 11:00 am – 12:30 pm
Auditorium Richelieu

Chairs: Prasad Iyer (USA) – Marcia (Mimi) Canto (USA)

  1. How should patients with established Barrett’s esophagus be followed? – Kerry Dunbar (USA)
  2. Is long-term surveillance necessary for low-risk patients? – Jason Samarasena (USA)
  3. Should all patients with dysplasia undergo ablation? – Shai Friedland (USA)
  4. How should Barrett’s esophagus with nodularity be treated? – Massimiliano Di Pietro (UK)
  5. How should patients be followed after endoscopic ablation? – Margaret Zhou (USA)
  6. Will artificial intelligence change the management of Barrett’s esophagus? – Chamil Codipilly (USA)

Panel Chat/Q&A

 

 

Session 30: Esophageal Pathology – Key Controversies and Updates

Wednesday, June 17, 11:00 am – 12:30 pm
Auditorium Condé

Chairs: Dhanpat Jain (USA) – Rupert Langer (Austria)

  1. Are the histologic features of ICI induced esophagitis specific? – Sara Hafezi Bakhtiari (Canada)
  2. What are the challenges with PDL1 scoring (CPS/TAP) for esophageal carcinoma? – Catherina Streutker (Canada)
  3. What are the challenges of margins evaluation for dysplasia carcinoma in ESD for esophageal neoplasia: Does it even matter? – Mikhail Lisovsky (USA)
  4. Is there a need to count Eosinophils in biopsies during follow-up of EOE biopsies during follow-up of EOE? – Suntrea Hammer (USA)
  5. Is there any role in sub-typing BE dysplasia: Intestinal vs. foveolar? – Dhanpat Jain (USA)
  6. What is the significance of epidermoid metaplasia in the esophagus? – Xuchen Zhang (USA)
  7. What are the challenges of evaluation and reporting of p53 in BE for dysplasia? – Ilke Nalbantoglu (USA)
  8. What are the advantages and disadvantages of various systems for evaluating post-therapy tumor regression? – Rupert Langer (Austria)
  9. Current role of digital pathology and AI in esophageal carcinoma and treatment response? – Bastian Dislich (Switzerland)
  10. Updates on WHO classification 6th edition and staging of esophageal carcinoma? – Deyali Chatterjee (USA)
  11. What are current and upcoming biomarkers for esophageal carcinomas? – Bella Liu (USA)

 

Session 31: GERD: Nuts and Bolts

Wednesday, June 17, 12:30 – 2:00 pm
Auditorium Lulli

 

Chairs: Mark Fox (Switzerland) – Kerry Dunbar (USA)

  1. How should the optimal reflux monitoring modality and protocol be selected for different reflux presentations? – Daniela Jodorkovsky (USA)
  2. Can patients with AET <4% off PPI have actionable GERD? – Wei-Yi (Ray) Lei (Taiwan)
  3. How should reflux-symptom association data on reflux monitoring tests be used for planning symptom management? – Kenneth Vega (USA)
  4. What is the optimal management for reflux hypersensitivity. – Neha Patel (USA)
  5. The AET is 4-6% off PPI – now what? – Nicola De Bortoli (Italy)
  6. Can total reflux episode count on impedance monitoring direct management? – Benjamin Rogers (USA)

    Panel Chat/Q&A
     
  7. What methods are available for clinical measurement of esophageal mucosal integrity? – Rishi Naik (USA)
  8. What are the roles of mucosal impedance metrics in evaluating typical and atypical reflux symptoms? – Adriana Lazarescu (Canada)
  9. Are there roles for barium esophagram and high-resolution manometry in GERD evaluation? – Stefano Siboni (Italy)
  10. How can FLIP be utilized for GERD diagnosis and management? – Abraham Khan (USA)
  11. What is the role of the brain-esophageal axis in reflux complications and extraesophageal symptoms? – Ming-Wun Wong (Taiwan)
  12. How can reflux management protect the lungs in pre- and post-transplant patients? – Wai-Kit Lo (USA)

Panel Chat/Q&A

 

Session 32: Challenging Cases in Surgery

Wednesday, June 17, 12:30 – 2:00 pm
Auditorium Richelieu

Chairs: Medhat Fanous (USA) – Dagmar Kollmann (Austria)

  1. No TIF where you live? A similar anti-reflux wrap can be performed laparoscopically. – Medhat Fanous (USA)
  2. Single stage definitive surgical repair of an aortoesophageal fistula. – Adam Zeyara (Sweden)
  3. Visualization of the antireflux wrap using Navicam technology in an awake patient. – Yaniv Cozacov (USA)
  4. Surgical approach to post-fundoplication outflow obstruction. – Renato Soares (Brazil)
  5. Antesternal, subcutaneous gastric pullup for necrosis after esophagectomy. – Yves Borbely (Switzerland)
  6. Re-operative para-conduit hernia repair after esophagectomy. – Ealaf Shemmeri (USA)
  7. Minimally invasive resection of a GIST of the gastroesophageal junction. – Stella Mantziari (Switzerland)
  8. When experts say “I Don’t Know”: A post esophagectomy paraesophageal hernia with intrathoracic bowel obstruction. – Phillip Woodworth (USA)
  9. Pericardial tracheoplasty with or without esophagectomy for chronic foreign-body induced tracheoesophageal fistula. – Russell White (Kenya)
  10. Dysphagia because of a localized mass – how to proceed? – Dagmar Kollmann (Austria)

Session 33: Challenging cases in Oncology

Wednesday, June 17, 12:30 – 2:00 pm
Auditorium Condé

Chairs: Manfred Lutz (Germany) – Ines Gockel (Switzerland) – Sara Lonardi (Italy) – Jean-Philippe Metges (France)

  1. HER2-Targeted Therapies:  new upcoming trials. – Alberto Puccini (Italy)
  2. Role of Immunotherapy for long-term survivorship. – Markus Moehler (Germany) 
  3. Claudin 18.2 Therapies for Gastroesophageal Cancer: full remission possible? – Jean-Philippe Metges (France)
  4. Thinking out of the box with localized disease or TNT. – Ines Gockel (Switzerland)
  5. CtDNA guidance? PLAGAST and more. – Catherine Streutker (Canada)
  6. When de-escalation after first line? – Sara Lonardi (Italy) 
  7. Liver limited disease: resect metastases like in colon cancer? – Beat Müller (Switzerland) 
  8. Oral Abstract Presentation: Comparative Outcomes of Neoadjuvant Immunochemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Cancer: A Real-World Study. – Zhiyu Li (China)
  9. Oral Abstract Presentation: Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study. – Yuquan Bai (China) 
  10. Final discussion: Next challenges in esophageal cancer: ALL participants

Session Format:
Presentations: Nine topics will be addressed with prepared presentations.
Each speaker will be given 10 minutes to discuss the assigned topic. 

 

 

 

 

 

Conference Speakers

S = Session | CS = Chair | MS = Moderators | DS = Discussant  | OC = Opening Ceremony  | CPS = Chair Poster Session
MC = Motility course | CMC = Chair Motility course | PMC = Presenter Motility course | DMC = Discussant Motility course

 

  • Nitin Ahuja (USA) – S28
  • Jacqueline Allen (New Zealand) – S7 – DS7 – CS24 – S24
  • Aymen AlMuhaidb (Saudi Arabia) – S28
  • Thierry André (France) – S1
  • Daphne Ang (Singapore) – S25
  • Emanuele Asti (Italy) – S19 – CS27 – S27
  • Yuquan Bai (China) – S33
  • Chang Seok Bang (Korea) – S9
  • Claudia Barber-Caselles (Spain) – S25
  • Alberto Barchi (Italy) – S25
  • Anastasia Bartashova – DS16
  • Rahul Bharadwaj (OESO, Malaysia) – S10
  • Ahmad Najdat Bazarbashi (Saudi Arabia) – S6 – S28
  • Reginald Bell (USA) – S19
  • Irit Ben-Aharon (Israel) – S1
  • Frank Benedix (Germany) – S14
  • Felix Berlth (Germany) – S8 – S17
  • Katharina Beyer (Germany) – S26
  • Claire Beveridge (USA) – S12 – S20
  • ​Jonathan Bock (USA) – DS7
  • Serhat Bor (Turkey) – DS7 – S13
  • Yves Borbely (Switzerland) – S15 – S32
  • So Young Byun (Korea) – S3 – S4
  • Marcia (Mimi) Canto (USA) – S19 – S27 – CS29
  • Thomas L. Carroll (USA) – S7 – DS7
  • Walter W. Chan (USA) – OC – CMC – DMC – CS2 – DS7 – S13 – S18 – SC20 – CS23 – CPS
  • Kenneth Chang (USA) – S19 – S23
  • Deyali Chatterjee (USA) – S30
  • Chien-Lin (Harry) Chen (Taiwan) – S2
  • Joan Chen (USA)  – DS25– S25
  • Judy Chen (USA) – S15
  • Mickael Chevallay (Switzerland) – S14
  • Philip Chiu (Hong Kong) – CS6 – S6 – S10 – DS19
  • Yu Kyung Cho (Korea) – S18
  • Reena Chokshi (USA) – S25
  • Cheol Woong Choi (Korea) – S6
  • Seung-Hun (Daniel) Chon (Germany)  – S9 
  • John O. Clarke (USA) – OC – DMC – S12 – CS20
  • Chamil Codipilly (USA) – S29
  • Yaniv Cozacov (USA) – S32
  • Enrique Coss-Adame (Mexico) – S23
  • Tanuja Damani (USA) – S11 – S23
  • Nicola de Bortoli (Italy) – S13 – S31
  • Hiroyuki Daiko (Japan) – S8
  • Christelle De la Fouchardière (France) – CS1 – S1 
  • Jonathan Delong (USA) – S16 – DS16
  • Giovanni De Manzoni (Italy) – CS14 – S14
  • Massimiliano Di Pietro (UK) – S27 – S29
  • Bastian Dislich (Switzerland) – S30
  • Yanhua Duan (China) – S3 
  • Kerry Dunbar (USA) – CS18 – S27 – S29 – CS31
  • Anneli Elme – CS22 – S22 
  • Moustafa Elshafai (Germany) – CS26
  • Jorge Luis Espinoza Rios (Peru) – DS25 – S25
  • Vincent Wentao Fang (China) – CS17
  • Medhat Fanous (USA) – S19 – CS32 – S32 
  • Ronnie Fass (USA) – S5 – S13
  • Jonas Feilchenfeldt (Switzerland) – S22
  • Valter N. Felix (Brazil) – S19
  • Filippo Filicori (USA) – S16 – DS16 
  • Mark Fox (Switzerland) – S13 – S23 – CS31
  • Shai Friedland (USA) – S6 – S27 – S29
  • Sravanya Gavini (USA) – MC – PMC
  • Gaurav Ghosh (USA) – MC – PMC
  • Simone Giacopuzzi (Italy) – S8 – S26
  • Mike Gibson (USA) – S1 – S3 – CS22 – S22
  • Suzanne Gisbertz (The Netherlands) – S10
  • Robert Giuli (France) – OC – S10
  • Ines Gockel (Switzerland) – S10 – S17 – S27 – CS33– S33
  • Nirmala Gonsalves (USA) – CS12 – S13 – S20
  • Peter Grimminger (Germany) – S8 – CS11 – CS17 
  • Livia Guadagnoli (USA) – S2
  • Maha M. Guindi (USA) – S16 – S27
  • Christian Gutschow (Switzerland) – S14
  • C. Prakash Gyawali (USA) – OC – CMC – DMC – CS2 – CS5 – CS13 – S13 – S18 – CS23
  • Suntrea Hammer (USA) – S30
  • Albis Hani (Colombia) – DS18 – S25
  • David Hartnett (USA) – S4
  • Joo Ha Hwang (USA) – S6 
  • Brent Hiramoto (USA) – S28
  • Arnulf H. Hölscher (Germany) – OC – CS14 – CS26
  • Toshitaka Hoppo (USA) – S6 – CS19
  • Jennifer Horsley-Silva (USA) – DS12 – S12
  • Po-Kuei Hsu (Taiwan) – S4
  • Joo Ha Hwang (USA) – CS6 – S9
  • Prasad Iyer (USA) – S27 – CS29
  • Gretchen Purcell Jackson (USA) – CS16 – S16 – MS16
  • Dhanpat Jain (USA) – S10 – CS30 – S30
  • Yan Jiang (USA)  – MC – PMC
  • Daniela Jodorkovsky (USA) – CS25 – S25 – S31
  • Nikki Johnston (USA) – CS3 – CS7 – S7 – S10 – S13
  • Moon Kyung Joo (Korea) – S6
  • Kee Wook Jung (Korea) – S18 – CS27
  • Da Hyun Jung (Korea) – S9
  • Hwoon-Yong Jung (Korea) – CS9 – S22
  • Minoa K. Jung (Switzerland) – CS28 – S28
  • Allon Kahn (USA) – S15
  • Anthony Kalloo (USA) – S6 – CS28
  • Hanoch Kashtan (Israel) – S1
  • Priya Kathpalia (USA) – MC – PMC
  • Kourtney L. Kemp (USA) – S15
  • Abraham Khan (USA) – S31
  • Mouen Khashab (USA) – CS6 – S6 – S9 
  • Byung-Wook Kim (Korea) – CS6 – CS9
  • Do Hoon Kim (Korea) – S18
  • Jennifer Klasen (Switzerland) – S11
  • Dagmar Kollmann (Austria) – CS32 – S32
  • Ludwig Kramer (Austria) – S21
  • Yusef Kudsi (USA) – CS11
  • Braden Kuo (USA) – S5
  • Jasmina Kuvendjiska (Germany) – S8
  • Rupert Langer (Austria) – S16 – DS16 – S22 – CS30 – S30
  • Adriana Lazarescu (Canada) – S31
  • Jérôme R. Lechien (Belgium)  – S7 – DS7 – S10
  • Ju Yup Lee (Korea) – S18
  • Sang Kil Lee (Korea) – CS18
  • Wei-Yi (Ray) Lei​ (Taiwan) – S31
  • Johannes Lenglinger (Switzerland) – S15
  • Zhiyu Li (China) – S33
  • Bella Liu (USA) – S30
  • Mikhail Lisovsky (USA) – S30
  • Wai-Kit Lo (USA) – S31
  • Nayna Lodhia (USA) – S28
  • Sara Lonardi (Italy) – CS33 – S33
  • Vladimir Lozanovski (Germany) – S4
  • Karolina Lungova (USA) – S3
  • Manfred Lutz (Germany) – CS1 – S1 – CS22 – CS33
  • Kristle Lynch (USA) – S25
  • Pavan Mallur (USA) – S7
  • Stella Mantziari (France) – S32
  • Styliani Mantziari (Switzerland) – S22
  • Celia Marginean (USA) – S30
  • Tomoaki Matsumura (Japan) – S6
  • Emily McGowan (USA) – DS12 – S12 – S20
  • Calies Menard-Katcher (USA) – S12
  • Paul Menard-Katcher (USA) – MC – PMC
  • Nainika Menon (UK) – S15
  • Helmut Messmann (Germany) – DS6 – S6 – DS9
  • Jean-Philippe Metges (France) – CS33 – S33
  • Markus Moehler (Germany) – OC – CS1 – S22– S33
  • Andrés Francisco Navarrete Molina (Chile) – CS8 – S8
  • Stefan Mönig (Switzerland) – OC – CS9 – CS14
  • Jacob Moremen (USA) – S15
  • Paulo Morgagni (Italy) – CS26
  • Mayssan Muftah (USA) – CS3 – S4  – S12
  • Amanda Muir (USA) – S3 – CS18 – S18 – S20
  • Beat Müller (Switzerland) – S33
  • Rishi Naik (USA) – S15 – S31
  • Ilke Nalbantoglu (USA) – S30
  • Anh Nguyen (USA) – CMC – MC – S25 
  • Mark Noar (USA) – S7 – DS7
  • Jung-Hwan Oh (Korea) – DS18
  • Frank G. Ondrey (USA) – S10
  • Moo In Park (Korea) – CS18
  • Walter Park (USA) – S9
  • Neha Patel (USA) – S31
  • Silvana Perretta (France) – S6 – S11 – CS28 – S28
  • Katja Petrowski (Germany) – S1
  • Guillaume Piessen (France) – S17
  • Peter Pokieser (Austria) – S10 – S16 – CS21 – S21 – S24
  • Alberto Puccini (Italy) – S33
  • Daryl Ramai (USA) – S19 – S27
  • Derrick Randall (Canada) – S7
  • Jari Räsänen (Finland) – S17 
  • Karthik Ravi (USA) – S25 – S28
  • William Ravich (USA) – S12 – S21
  • Matthew Read (Australia) – CS8 – S10
  • José María Remes Troche (Mexico) – S2 – S5 – DMC – S13
  • Florence Renaud (France) – S30
  • Allyson Richardson (USA) – MC – PMC
  • Megan Riehl (USA) – S2
  • Benjamin Rogers (USA) – PMC – MC – CS15 – S16 – DS16 – S31
  • Sabine Roman (France) – S5
  • Nathalie Rommel (Belgium) – CS24 – S24
  • Rubens Sallum (Brazil)  – S11 – S17 – S26
  • Jason Samarasena (USA) – S16 – DS16 – S29
  • Tina Samuels (USA) – S7
  • Santosh Sanagapali (Australia) – S2
  • Inderpal (Netu) Singh Sarkaria (USA) – CS8 – S11 – S21
  • Ayodele Sasegbon (UK) – S24
  • Edoardo Savarino (Italy) – S5 – DS7 
  • Akinari Sawada (Japan) – PMC – S2
  • Carmelo Scarpignato (Malta) – CS13 – S13
  • Christoph Schlag (Switzerland) – S20
  • Paul Schneider (Switzerland)  – S14
  • Tilman Schlick (Germany) – S11
  • Allison R. Schulman (USA) – S28
  • Guido Schumacher (Italy) – CS17
  • Eric Shah (USA) – S16 – DS16 
  • Ealaf Shemmeri (USA) – CS4 – S32
  • Eric Sheu (USA) – S28
  • Eun Ji Shin (USA) – DS9 – CS19 – S27
  • Sung Kwan Shin (Korea) – DS6 – DS9
  • Stefano Siboni (Italy) – S4 – S7 – DS7 – S31
  • Alexander Siebenhuener – S22
  • Daniel Sifrim (UK) – CS5 – S13
  • Aleksandar P. Simić (Serbia) – S26
  • Joshua Sloan (USA) – S12 – CS25 – DS25
  • Diana Snyder (USA) – MC – PMC
  • Renato Soares (Brazil) – S32
  • Irene Sonu (USA) – PMC – MC
  • Marco Sozzi (Italy) – MC – PMC – S4 
  • Ellen M. Stein (USA) – CMC – DMC – S5 – S12 – S13 – CS25 
  • Alex Strauss (USA) – S12
  • Catherine Streutker (Canada) – S30 – S33
  • Lee L. Swanström (France) – CS16 – S16 – MS16 – CS19 – S19
  • Flavio Takeda (Brazil)  – CS11 
  • Roger Tatum (USA) – OC – DMC – PMC – CS15 
  • Eduardo Terán (Spain) – S1
  • Salvatore Tolone (Italy) – S23 – S28
  • Benjamin Tordjman (Canada) – S4 
  • Ping-Huei Tseng (Taiwan) – S15 – S19
  • Luis Raúl Valdovinos García (Mexico) – S4  – S25
  • Alexandra Vandenberg (USA) – S7
  • Kenneth Vega (USA) – S27 – S31
  • Felipe Victer (Brazil) – S11
  • Pierfrancesco Visaggi (Italy) – CS4 – CS12 – S20
  • Burkhard H.A. von Rahden (Germany) – S26
  • Kevin Waters (USA) – S12
  • Russell E. White (Kenya) – OC – S10 – S32
  • Ian Wong (Hong Kong) – S17
  • Marc Wong (Hong Kong) – MC – PMC
  • Ming-Wun Wong (Taiwan) – S31
  • Phillip Woodworth (USA) – S32
  • Justin Wu (Hong Kong) – S13 – S23
  • Lucjan Wyrwicz (Poland) – S1
  • Şuayib Yalçın (Turkey) – S22
  • Hyo-Joon Yang (Korea) – S9
  • Johannes Zacherl (Austria) – S14 – CS21 – S21 – S24
  • Aziz Zaanan (France) – S1
  • Frank Zerbib (France) – CS7 – S10
  • Adam Zeyara (Sweden) – S32
  • Xuchen Zhang (USA) – S30
  • Bruno Zilberstein (Brazil) – S10
  • Margaret Zhou (USA) – CS27 – S27 – S29
  • BenBen Zhu (China) – S3 – S22